Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Sees Large Growth in Short Interest

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totaling 16,586 shares, an increase of 51.0% from the July 15th total of 10,987 shares. Approximately 3.3% of the company’s stock are sold short. Based on an average trading volume of 80,891 shares, the short-interest ratio is presently 0.2 days.

Analysts Set New Price Targets

ELOX has been the subject of several analyst reports. Weiss Ratings initiated coverage on Eloxx Pharmaceuticals in a research note on Friday. They set a “sell (d)” rating for the company. Lifesci Capital began coverage on Eloxx Pharmaceuticals in a research note on Wednesday, July 22nd. They issued an “outperform” rating and a $40.00 price objective for the company. Guggenheim initiated coverage on Eloxx Pharmaceuticals in a research report on Monday, July 20th. They set a “buy” rating and a $43.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Eloxx Pharmaceuticals to a “hold” rating in a research note on Saturday, August 1st. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Eloxx Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $41.50.

Eloxx Pharmaceuticals Trading Down 3.3%

Shares of ELOX traded down $0.60 during mid-day trading on Wednesday, reaching $17.65. The company’s stock had a trading volume of 35,979 shares, compared to its average volume of 55,100. Eloxx Pharmaceuticals has a 12-month low of $8.20 and a 12-month high of $19.96. The firm has a market capitalization of $12.18 million, a PE ratio of -1.15 and a beta of -1,863.11. The firm’s 50 day moving average price is $13.92.

Eloxx Pharmaceuticals (NASDAQ:ELOX) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.66) EPS for the quarter.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.